Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 12;8(4):978–990. doi: 10.1182/bloodadvances.2023012120

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 3. — Outcomes after Ven plus FluBu2 allo-SCT followed by Ven/Aza maintenance. (A) Swimmer plot for the intent-to-treat cohort (N = 27) and time to death or last known alive. Shown with accompanying heat map for disease status over time (D0, D28, D100, 6M, and 12M), maintenance receipt, and survival status. D0, day 0; D28, day +28 after transplant; D100, day +100 after transplant; 6M, 6 months after transplant; and 12M, 12 months after transplant. Relapse indicated by red-filled triangle. (B) Kaplan-Meier estimate and log-rank test of OS (blue line), PFS (red line), and relapse (green line) in the intent-to-treat cohort (top, N = 27) and in the cohort that ultimately received maintenance Ven/Aza (bottom, N = 22). 95% CIs are reported for each outcome.